Sorrento Therapeutics Inc (SRNE) Börsenkurse

Form 8-K - Current report

Form 8-K - Current report

Form 8-K - Current report

Form 8-K - Current report

Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB

Form 8-K - Current report

Form 8-K - Current report

Shanghai Escugen Biotechnology Co., Ltd., a partner of Levena Biopharma, a Sorrento Company, releases positive results from a first-in-human study of ESG401, a TROP2 Antibody Drug Conjugate in patients with locally advanced/metastatic solid tumors at the A

CHICAGO, June 05, 2023 (GLOBE NEWSWIRE) -- Shanghai Escugen Biotechnology Co., Ltd. (“Escugen”), a partner of Levena (Suzhou) Biopharma Co., Ltd. (“Levena”), a wholly owned subsidiary of...

Sorrento Therapeutics, Inc. Receives Court Approval for $75 Million Financing in Chapter 11 Case

Sorrento Therapeutics, Inc. Receives Court Approval for $75 Million Financing in Chapter 11 Case PR Newswire SAN DIEGO, Feb. 21, 2023 SAN DIEGO, Feb. 21, 2023 /PRNewswire/ -- Sorrento...

Sorrento Posts Form 8937 to Supplement its Previously Issued “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock (Nasdaq: SCLX, “Scilex”)

SAN DIEGO, Feb. 18, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today posted an IRS Form 8937 (the “Form 8937”) to supplement its previously issued...